BridgeBio Pharma (BBIO) Times Interest Earned (2018 - 2026)
BridgeBio Pharma (BBIO) posted Times Interest Earned of -$5.22 for Q1 2026, up 64.75% sequentially from -$14.8 in Q4 2025, and down 16.28% YoY from -$6.23 in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Times Interest Earned (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Times Interest Earned for 9 years, with the latest figure at -$5.22 in Q1 2026.
- Quarterly Times Interest Earned fell 16.28% year-over-year to -$5.22 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.94 (down 7.82% YoY) and the FY2025 annual result came in at -$0.54, up 33.68% from the prior year.
- Times Interest Earned advanced to -$5.22 in Q1 2026 per BBIO's latest filing, from -$14.8 in the prior quarter.
- Over five years, Times Interest Earned peaked at $0.01 in Q1 2024 and troughed at -$17.25 in Q4 2024.
- A 5-year average of -$6.33 and a median of -$5.82 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned soared 100.17% in 2024, then plunged 46277.89% in 2025.
- Over 5 years, Times Interest Earned stood at -$6.46 in 2022, then climbed by 9.91% to -$5.82 in 2023, then plunged by 196.12% to -$17.25 in 2024, then advanced by 14.21% to -$14.8 in 2025, then jumped by 64.75% to -$5.22 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$5.22, -$14.8, and -$2.34 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | -8.06 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.06 |
| Mar 31, 2026 | -8.19 |
| Dec 31, 2025 | -11.99 |
| Sep 30, 2025 | -12.37 |
| Jun 30, 2025 | -11.57 |
| Mar 31, 2025 | -5.76 |
| Dec 31, 2024 | -10.50 |
| Sep 30, 2024 | -8.31 |
| Jun 30, 2024 | -7.65 |
| Mar 31, 2024 | 0.01 |
| Dec 31, 2023 | -8.75 |
| Sep 30, 2023 | -7.77 |
| Jun 30, 2023 | -7.09 |
| Mar 31, 2023 | -6.27 |
| Dec 31, 2022 | -6.46 |
| Sep 30, 2022 | -6.51 |
| Jun 30, 2022 | -3.95 |
| Mar 31, 2022 | -8.54 |
| Dec 31, 2021 | -10.94 |
| Sep 30, 2021 | -13.51 |